Buy Aster DM Healthcare; target of Rs 400: Prabhudas Lilladher

Buy

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

live

• bselive
• nselive

Volume

Todays L/H

More

×

Prabhudas Lilladher's research report on Aster DM Healthcare

ASTER DM Healthcare (ASTERDM) Q4 consolidated EBITDA grew strong by 29% YoY to Rs1.6bn. GCC stake sale concluded in Mar’24 and the company distributed 80% of proceeds as a one-time dividend. ASTERDM India’s EBITDA increased sharply over the last 3 years (29% CAGR over FY22-24). We estimate 30% EBITDA CAGR over FY24-26E aided by scale-up in margins, healthy ARPOB and bed additions. Our FY25E/26E estimates for India business EBITDA remain unchanged. At current market price, the stock is trading at 20x EV/EBITDA on FY26E, respectively adjusted for minority stake and rental.

Outlook

We maintain ‘Buy’ rating with TP of Rs400, valuing the India hospital segment at 23x EV/EBITDA on FY26E EBITDA. Utilization of proceeds and timely expansion will be key monitorables in the near term.

For all recommendations report, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

Aster DM Healthcare - 30052024 - prabhu